Abstract
Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1480-1484 |
| Number of pages | 5 |
| Journal | Clinical Infectious Diseases |
| Volume | 54 |
| Issue number | 10 |
| DOIs | |
| State | Published - May 15 2012 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Miconazole mucoadhesive tablets: A novel delivery system'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS